NCT02722447

Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,100 (estimated)
• Sponsor: Walter Ageno · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The treatment of isolated distal deep vein thrombosis remains one of the most debated issues in the field of venous thromboembolism and only very few studies have directly addressed the issue of treatment in objectively confirmed isolated distal deep vein thrombosis. Aim of this study is to assess the long-term risk of recurrent venous thrombotic events in patients with a first acute symptomatic isolated distal deep vein thrombosis of the leg treated with a standard (12 weeks) or with a shorter (6 weeks) duration of therapy with rivaroxaban.

Conditions

• Deep Vein Thrombosis

Interventions

Type	Name	Description
DRUG	rivaroxaban	Rivaroxaban 20 mg for 6 weeks
DRUG	Placebo	Placebo for 6 weeks

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-06-01
• Completion: 2021-06-01
• First posted: 2016-03-30
• Last updated: 2018-11-27

Locations

7 sites across 1 country: Italy